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Metabolism of messenger RNAs (mRNAs) consists 
of multiple steps, from transcription, through splicing, 
export to the cytoplasm, localization, translation to 
proteins and, finally, degradation. These steps, which are 
crucial to ensure correct genetic expression, have long 
been considered as separate events occurring at distinct 
time points and different locales. Recent studies suggest 
that they are not only interconnected, but might also be 
coupled to the initial process - transcription. 
Initial studies in the field showed that the occurrence 
of exon inclusion and intron retention could be altered in 
HEK293 cells with “slow” and “fast” RNA Polymerase 
II (RNAPII) mutants, suggesting that the rate of 
transcriptional elongation is crucial for the appropriate 
splice form [1]. Another important step of mRNA life is 
its export from the nucleus into the cytoplasm. It has been 
suggested that the export is not merely a sequential event, 
but a tightly regulated process that might depend upon 
transcription. In yeast, a group of factors that function 
in transcription elongation and mRNA export form a 
“Transcription/Export” (TREX) complex, which couples 
to RNA Pol II throughout the entire RNA molecule [2]. 
As splicing and export could occur co-
transcriptionally, they might be directly affected by 
the dynamics of transcription. However, how post-
transcriptional processes - such as degradation and 
translation - could be coupled to transcription? When a 
single-molecule mRNA decay study measured stabilities 
of two mitotic mRNAs, SWI5 and CLB2 in yeast, they 
found that the precise control of their cytoplasmic decay is 
largely regulated by their promoters via co-transcriptional 
binding of a co-factor, Dbf2p [3]. Similarly, Bregman et al. 
showed that promoter sequences can recruit Rap1p protein 
to enhance the decay of the transcribed mRNA in yeast 
[4]. Thus promoters, elements that drive the transcription, 
are capable of regulating the destiny of mRNAs after its 
export into the cytoplasm. Recent evidences from several 
studies suggest that also the mRNA translation could be 
regulated, to a large extent, by transcription. First, yeast 
promoters were shown to recruit RNAPII subunits to 
facilitate translation of specific transcripts [5]. Similarly, 
upon glucose starvation, specific yeast promoters were 
shown to bind Hsf1 to direct mRNA localization and the 
efficiency of translation in the cytoplasm [6]. These two 
studies demonstrate the ability of yeast promoters, via co-
transcriptional recruitment of effector proteins, to regulate 
translation of specific mRNAs. 
Recently, we discovered a direct genome-wide 
link between transcription and translation in mammalian 
cells [7]. While testing the effect of human promoters on 
translation, we identified a positive correlation between 
the levels of mRNA expression on their capabilities to bind 
ribosomes (i.e., translational efficiency, or TE). However, 
we observed that mRNA levels present in the cytoplasm 
are not the factor that dictates TE directly. Instead, we 
found that rates of transcription (i.e. the strength of the 
promoter activity to recruit RNAPII and the speed of 
transcriptional elongation) positively regulate TE across 
different mammalian cell lines. 
To study how this link is maintained, we examined 
a possible role of a specific RNA modification, N6-
methyladenosine (m6A), in coordinating the two 
processes [7]. Indeed, upon knock-down of several 
m6A-regulatory factors, both “writers” and “readers”, 
we observed a striking positive effect on the TE of 
mRNA that was characterized by slow transcription 
rates. Direct immunoprecipitation of m6A-modified 
mRNAs demonstrated significant difference between 
the methylation levels of the repressed and induced 
transcripts, suggesting that mRNAs that are “repressed” 
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Figure 1: Different transcription rates dispose distinct m6A footprint on mRNAs, which profoundly impact translation 
efficiency.
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(i.e., possess low levels of transcription), have higher 
m6A content. This, in turn, represses TE, therefore linking 
inefficient transcription to inefficient translation. Finally, 
by artificial slow-down of RNAPII dynamics, we showed 
that the process of m6A modification on mRNA is likely to 
be co-transcriptional.
Our study provides an additional evidence that 
transcription machinery is intrinsically linked with the 
process of translation and support the theory that the fate of 
a mRNA molecule could be in part pre-determined during 
transcription. Future studies should address the hidden 
link between RNAPII and m6A methylation complex and 
reveal how the speed of RNAPII is translated into the m6A 
content deposited on the transcript. Additionally, the exact 
role of m6A in translation still remains ambiguous. While 
we proposed an inhibitory role of m6A in translation, 
several recent studies found it stimulatory [e.g., 8]. The 
paradox could be partially explained by the precise 
location of the modified residue within the transcript 
(e.g., coding region versus untranslated regions). Future 
research should examine this hypothesis and uncover how 
cells determine the precise sites of m6A deposition. 
mRNAs are modified by a myriad of epigenetic 
modifications of which little functional knowledge is 
present. The functional investigation of the role of these 
RNA modifications is just emerging, and is expected to 
increase in volume in the coming few years. With the 
increasing knowledge of m6A regulation, its role in gene 
expression, involvement in diseases and the potential to 
serve for diagnosis (e.g. in cancer) is expected to become 
much clearer in the near future. The possible applications 
of RNA modifications, including drug development 
targeting m6A machineries and thus altering the epigenetic 
environment, could open up new avenues to a better and 
more effective diagnosis and treatment of human diseases 
stemming from imbalanced gene expression.
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